European Society of Cardiology (ESC) Congress 2026 | News | Updates | iPharmaCenter

---

Camzyos Sustains Symptom and Heart Function Gains Through Five Years, New Data Show

Bristol Myers Squibb presented new long-term and real-world evidence supporting Camzyos, also known as mavacamten, for people living with symptomatic obstructive hypertrophic cardiomyopathy at the European Society of Cardiology Congress 2026 in Munich.

The findings reinforce that treatment benefits with Camzyos can be sustained for up to five years, adding to what the company describes as the most extensive clinical evidence base among cardiac myosin inhibitors.

Longest Follow-Up Study of Its Kind

The centerpiece of the presentation was data from the EXPLORER-LTE cohort within the broader MAVA-LTE study. This research represents the largest and longest evaluation to date of patients with obstructive hypertrophic cardiomyopathy treated with Camzyos.

EXPLORER-LTE is a single-arm, open-label, dose-blinded extension of the earlier Phase 3 EXPLORER-HCM trial. A total of 231 patients from the United States, Europe, and Israel who completed the original study chose to continue into this long-term follow-up.

Sustained Improvements at Five Years

At 252 weeks of continued treatment, patients showed meaningful reductions in the heart obstruction associated with this condition.

Compared with levels recorded when the extension study began, the average resting left ventricular outflow tract gradient fell by 38.7 millimeters of mercury, while the Valsalva gradient decreased by 55.6 millimeters of mercury.

Almost all patients, 97.4%, reached a Valsalva gradient at or below 30 millimeters of mercury, the clinical threshold used to define obstruction in this disease.

More than two-thirds of participants, 69.6%, improved by at least one New York Heart Association functional class, and 59.2% became free of symptoms. Average left ventricular ejection fraction declined slightly by 10.2% but stayed within the normal range, indicating that heart pumping function remained stable.

Bristol Myers Squibb reported that no new safety concerns emerged beyond what was already documented in the original EXPLORER-HCM trial.

Real-World Evidence Reinforces Trial Findings

Beyond the extension study, additional research presented at the meeting examined how Camzyos performs outside controlled clinical trials.

Two analyses from COLLIGO-HCM, a global retrospective study using real-world data, found that the medicine’s effectiveness and safety profile in routine clinical practice were consistent with results seen in earlier studies. Patients in this real-world setting experienced symptom improvement and reduced outflow tract obstruction.

A separate observational registry analysis conducted in Germany produced similar findings, with patients experiencing functional class improvements that mirrored outcomes from other real-world studies. Together, these results suggest that benefits seen in formal clinical trials extend into everyday medical practice across different patient populations.

Understanding the Broader Burden of the Disease

A healthcare resource utilization study conducted in Sweden was also presented, offering insight into the wider impact of hypertrophic cardiomyopathy and its obstructive form on patients and health systems.

The analysis underscored the importance of timely diagnosis and consistent long-term care for people living with this condition, given the disease’s ongoing burden on health resources.

About Camzyos and it's mechanism of action

Camzyos, known generically as mavacamten, is a selective and reversible inhibitor of cardiac myosin. It is approved by regulatory authorities in more than 60 countries and regions worldwide.

In the United States, Camzyos is approved for adults with symptomatic New York Heart Association class II to III obstructive hypertrophic cardiomyopathy to help improve functional capacity and reduce symptoms. In the European Union, it carries a similar approved use for adult patients with symptomatic disease in the same functional classes.

The medicine works by targeting the excessive heart muscle contraction that underlies this form of cardiomyopathy. By reducing that contractility, Camzyos can ease outflow tract obstruction, improve the heart’s energy efficiency, and lower internal cardiac pressures. It may be used with or without other background therapies, including in patients who are newly diagnosed.

Bristol Myers Squibb said Camzyos has now been prescribed by more than 5,000 healthcare providers to over 25,000 patients in the United States alone, reflecting its growing role as a standard treatment option for this rare heart condition.